120 related articles for article (PubMed ID: 8474285)
1. [Fulminant meningococcemia treated with antiendotoxin IgM monoclonal antibodies (HA-1A)].
Gómez-Jiménez J; Peracaula Picart R; Jódar Masanes R; Montoro Ronsano B
Med Clin (Barc); 1993 Mar; 100(10):394-5. PubMed ID: 8474285
[No Abstract] [Full Text] [Related]
2. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.
Derkx B; Wittes J; McCloskey R
Clin Infect Dis; 1999 Apr; 28(4):770-7. PubMed ID: 10825037
[TBL] [Abstract][Full Text] [Related]
3. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
[No Abstract] [Full Text] [Related]
4. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia.
Zenz W; Muntean W; Gallistl S; Zobel G; Grubbauer HM
Pediatrics; 1995 Jul; 96(1 Pt 1):144-8. PubMed ID: 7596694
[No Abstract] [Full Text] [Related]
5. Monoclonal antibodies in the treatment of adult fulminant meningococcaemia.
Wester JP; Breumelhof R; Geers AB
Eur J Med; 1992 Oct; 1(6):372-3. PubMed ID: 1341468
[No Abstract] [Full Text] [Related]
6. Antiendotoxin therapy in sepsis.
Colletti RC; Dew RB; Goulart AE
Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
[TBL] [Abstract][Full Text] [Related]
7. Comparison of HA-1A and E5 monoclonal antibodies to endotoxin in rats with endotoxaemia.
Boom SJ; Davidson JA; Zhang P; Reidy J; Ramsay G
Eur J Surg; 1993 Oct; 159(10):559-61. PubMed ID: 8286515
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
9. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator.
Zenz W; Muntean W; Zobel G; Grubbauer HM; Gallistl S
Thromb Haemost; 1995 Aug; 74(2):802-3. PubMed ID: 8585030
[No Abstract] [Full Text] [Related]
10. Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA.
Wenzel RP; Andriole VT; Bartlett JG; Batt MD; Bullock WE; Cobbs CG; Light B; Martin MA; Sanford J; Sande MA
Clin Infect Dis; 1992 Apr; 14(4):973-6. PubMed ID: 1482434
[No Abstract] [Full Text] [Related]
11. Antiendotoxin monoclonal antibodies for gram-negative sepsis.
Chmel H; Emmanuel G
Clin Infect Dis; 1992 Aug; 15(2):371-2. PubMed ID: 1520771
[No Abstract] [Full Text] [Related]
12. Protein C replacement in severe meningococcemia: rationale and clinical experience.
Alberio L; Lämmle B; Esmon CT
Clin Infect Dis; 2001 May; 32(9):1338-46. PubMed ID: 11303270
[TBL] [Abstract][Full Text] [Related]
13. Antiendotoxin antibodies.
Siegel JP
Ann Intern Med; 1995 Feb; 122(4):315-6. PubMed ID: 7825773
[No Abstract] [Full Text] [Related]
14. 50 Years Ago in TheJournal ofPediatrics: Heparin Therapy in Fulminant Meningococcemia.
Dorn E; Toltzis P
J Pediatr; 2019 Sep; 212():207. PubMed ID: 31439162
[No Abstract] [Full Text] [Related]
15. Antiendotoxin antibodies: a dead end?
Cross AS
Ann Intern Med; 1994 Jul; 121(1):58-60. PubMed ID: 8198349
[No Abstract] [Full Text] [Related]
16. Hospital pharmacies brace for release of antiendotoxin monoclonal antibodies.
Am J Hosp Pharm; 1992 Apr; 49(4):740, 743-5. PubMed ID: 1595715
[No Abstract] [Full Text] [Related]
17. Criteria for use of antiendotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients.
Shepherd MF
Clin Pharm; 1992 Mar; 11(3):257-60. PubMed ID: 1611816
[No Abstract] [Full Text] [Related]
18. Secondary hemophagocytic lymphohistiocytosis associated with meningococcemia.
Dinleyici EC; Bor O; Kiremitci A; Aksit MA
Pediatr Hematol Oncol; 2006 Dec; 23(8):683-6. PubMed ID: 17065145
[No Abstract] [Full Text] [Related]
19. Oral antibiotics and outcome in meningococcemia.
Radetsky M
Arch Intern Med; 2000 Jul; 160(14):2220-3. PubMed ID: 10904473
[No Abstract] [Full Text] [Related]
20. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
Luce JM
Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
